PMPatrizio Mattei

Patrizio Mattei

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Patrizio Mattei has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • Christoph Bieniossek

    Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

    5 shared publications
  • Daniel Kahne

    Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA

    5 shared publications
  • Fabian Dey

    Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

    5 shared publications
  • Karanbir S. Pahil

    Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA

    5 shared publications
  • Kenneth Bradley

    Departments of Immunology, Infectious Disease and Ophthalmology (I2O), Medicinal Chemistry and Lead Discovery, Roche Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

    5 shared publications
  • Thomas Clairfeuille

    Roche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland

    5 shared publications

Latest Publications

  • Open Access

    Author Correction: A novel antibiotic class targeting the lipopolysaccharide transporter

    by Claudia Zampaloni, Patrizio Mattei, Konrad Bleicher, Lotte Winther, Claudia Thäte, Christian Bucher, Jean-Michel Adam, Alexander Alanine, Kurt E. Amrein, Vadim Baidin, et al.


  • Open Access

    Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter

    by Karanbir S. Pahil, Morgan S. A. Gilman, Vadim Baidin, Thomas Clairfeuille, Patrizio Mattei, Christoph Bieniossek, Fabian Dey, Dieter Muri, Remo Baettig, Michael Lobritz, et al.


  • Open Access

    Author Correction: A new antibiotic traps lipopolysaccharide in its intermembrane transporter

    by Karanbir S. Pahil, Morgan S. A. Gilman, Vadim Baidin, Thomas Clairfeuille, Patrizio Mattei, Christoph Bieniossek, Fabian Dey, Dieter Muri, Remo Baettig, Michael Lobritz, et al.


  • Top Cited Papers
    Open Access

    A novel antibiotic class targeting the lipopolysaccharide transporter

    by Claudia Zampaloni, Patrizio Mattei, Konrad Bleicher, Lotte Winther, Claudia Thäte, Christian Bucher, Jean-Michel Adam, Alexander Alanine, Kurt E. Amrein, Vadim Baidin, et al.

    Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.


  • Top Cited Papers
    Open Access

    A new antibiotic traps lipopolysaccharide in its intermembrane transporter

    by Karanbir S. Pahil, Morgan S. A. Gilman, Vadim Baidin, Thomas Clairfeuille, Patrizio Mattei, Christoph Bieniossek, Fabian Dey, Dieter Muri, Remo Baettig, Michael Lobritz, et al.

    Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.